Evidence map›Paper›PMID 37341059›Full record

ArticleMolecular oncology2023

Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma.

Kathrin Hedegger, Andreas Blutke, Theresa Hommel, Kerstin E Auer, Nishanth B Nataraj, Moshit Lindzen, Yosef Yarden, Maik Dahlhoff

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Kathrin HedeggerInstitute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU München, Germany.
Andreas BlutkeInstitute of Veterinary Pathology, Center for Clinical Veterinary Medicine, LMU München, Germany.
Theresa HommelInstitute of in vivo and in vitro Models, University of Veterinary Medicine, Vienna, Austria.
Kerstin E AuerInstitute of in vivo and in vitro Models, University of Veterinary Medicine, Vienna, Austria.
Nishanth B NatarajDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
Moshit LindzenDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
Yosef YardenDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
Maik DahlhoffInstitute of in vivo and in vitro Models, University of Veterinary Medicine, Vienna, Austria.ORCID 0000-0001-9189-7631
University of Veterinary Medicine Vienna · ATLudwig-Maximilians-Universität München · DEWeizmann Institute of Science · ILCellworks Research (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest of cancers. Attempts to develop targeted therapies still need to be established. Some oncogenic mechanisms in PDAC carcinogenesis harness the EGFR/ERBB receptor family. To explore the effects on pancreatic lesions, we attempted simultaneous blockade of all ERBB ligands in a PDAC mouse model. To this end, we engineered a molecular decoy, TRAP-F

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsDisease Models, AnimalErbB ReceptorsHumansLigandsMiceMice, Inbred CBAMice, TransgenicProto-Oncogene Proteins p21(ras)Receptor, ErbB-4EGFR protein, mouseErbB ReceptorsLigandsProto-Oncogene Proteins p21(ras)Receptor, ErbB-4decoy moleculeEGF-family ligandsERBB receptorsKrasmouse modelPanc-1PDAC

Identifiers

PMID37341059
PMCPMC10620123
OpenAlexW4381470692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.